Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 18 Sept 2025 for Y-mAbs Therapeutics, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
John LaRocca: trading record in brief
This profile gathers the share dealings of John LaRocca across 2 companies, led by Aerie Pharmaceuticals Inc and Y-mAbs Therapeutics, Inc. Over a trading history stretching from 14 August 2021 to 16 September 2025, the count stands at 9 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 18 September 2025 came the latest disclosure, a transaction in Y-mAbs Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to John LaRocca
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
21,500 sharesCommon StockSEC:0001732197-25-000005:0
21,500 shares0Common StockSEC:0001415889-25-001874:0
53,585 shares@ US$15.2592.6% of flowCommon StockSEC:0001209191-22-058180:0
771 shares@ US$11.571.0% of flowCommon StockSEC:0001209191-22-045976:0
19,015 shares0Common StockSEC:0001209191-22-020655:0
1,973 shares@ US$6.001.3% of flowCommon StockSEC:0001209191-22-012251:0
768 shares@ US$7.240.6% of flowCommon StockSEC:0001209191-22-008228:0
1,206 shares@ US$7.050.9% of flowCommon StockSEC:0001209191-22-007897:0
765 shares@ US$14.701.2% of flowCommon StockSEC:0001209191-21-051897:0
9 of 9 declarations
